Genexine Inc (095700) - Total Liabilities

Latest as of September 2025: ₩106.21 Billion KRW ≈ $71.98 Million USD

Based on the latest financial reports, Genexine Inc (095700) has total liabilities worth ₩106.21 Billion KRW (≈ $71.98 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Genexine Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.

Genexine Inc - Total Liabilities Trend (2009–2024)

This chart illustrates how Genexine Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Genexine Inc's balance sheet.

Genexine Inc Competitors by Total Liabilities

The table below lists competitors of Genexine Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Paseco Co. Ltd KQ:037070	Korea	₩33.66 Billion
Concorde International Group Ltd Class A Ordinary Shares NASDAQ:CIGL	USA	$7.57 Million
Kyungdong City Gas Co Ltd KO:267290	Korea	₩453.62 Billion
Embellence Group AB ST:EMBELL	Sweden	Skr248.00 Million
Apetit Oyj HE:APETIT	Finland	€37.60 Million
Builddirect.com Tehcnologies Inc V:BILD	Canada	CA$32.08 Million
Clipan Finance Indonesia Tbk JK:CFIN	Indonesia	Rp4.04 Trillion
Townsquare Media Inc NYSE:TSQ	USA	$583.33 Million

Liability Composition Analysis (2009–2024)

This chart breaks down Genexine Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 095700 equity to assets ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.58	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.41	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.29	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Genexine Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Genexine Inc (2009–2024)

The table below shows the annual total liabilities of Genexine Inc from 2009 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩83.36 Billion ≈ $56.49 Million	+4.62%
2023-12-31	₩79.68 Billion ≈ $54.00 Million	-29.25%
2022-12-31	₩112.63 Billion ≈ $76.33 Million	-5.45%
2021-12-31	₩119.12 Billion ≈ $80.73 Million	+94.32%
2020-12-31	₩61.30 Billion ≈ $41.54 Million	+0.06%
2019-12-31	₩61.27 Billion ≈ $41.52 Million	+12.82%
2018-12-31	₩54.30 Billion ≈ $36.80 Million	+102.44%
2017-12-31	₩26.83 Billion ≈ $18.18 Million	-5.77%
2016-12-31	₩28.47 Billion ≈ $19.29 Million	+74.28%
2015-12-31	₩16.33 Billion ≈ $11.07 Million	-6.94%
2012-12-31	₩17.55 Billion ≈ $11.89 Million	+15.89%
2011-12-31	₩15.14 Billion ≈ $10.26 Million	+34.71%
2010-12-31	₩11.24 Billion ≈ $7.62 Million	+162.52%
2009-12-31	₩4.28 Billion ≈ $2.90 Million	--

About Genexine Inc

KQ:095700 Korea Biotechnology

Market Cap

$87.38 Million

₩128.93 Billion KRW

Market Cap Rank

#19781 Global

#1021 in Korea

Share Price

₩2835.00

Change (1 day)

+1.43%

52-Week Range

₩2195.00 - ₩7100.00

All Time High

₩131402.78